Analysis shows antimicrobial resistance rates in pseudomonas aeruginosa from 68 clinical samples, suggesting urgent need for stronger antibiotic policies.
Key Points
Piperacillin-tazobactam demonstrated low resistance at 2.9%, indicating it remains effective against pseudomonas aeruginosa infections.
Imipenem resistance was notably high at 58.8%, highlighting a significant challenge in treating these infections effectively.
Retrospective analysis utilized clinical samples collected between January and September 2023 from a rural region.
Findings underscore the need for improved antibiotic stewardship to combat the rise of multi drug resistant pseudomonas aeruginosa.